検索
IO Biotech Inc
IOBTウォッチリストに追加
0.048USD
0.0000.00%
終値 05/15, 16:00（ET）15分遅れの株価
244.63K時価総額
損失額直近12ヶ月PER
詳細情報 IO Biotech Inc 企業名
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
IO Biotech Incの企業情報
企業コードIOBT
会社名IO Biotech Inc
上場日Nov 05, 2021
最高経営責任者「CEO」Zocca (Mai-Britt)
従業員数80
証券種類Ordinary Share
決算期末Nov 05
本社所在地Ole Maaloes Veh 3
都市COPENHAGEN
証券取引所NASDAQ OMX - NASDAQ BASIC
国Denmark
郵便番号2200
電話番号4570702980
ウェブサイトhttps://www.iobiotech.com/
企業コードIOBT
上場日Nov 05, 2021
最高経営責任者「CEO」Zocca (Mai-Britt)
IO Biotech Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+70.87%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
--
Dr. Peter Hirth, Ph.D.
Dr. Peter Hirth, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Christian E. Elling, Ph.D.
Dr. Christian E. Elling, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Mr. David V. Smith
Mr. David V. Smith
Independent Director
Independent Director
--
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
--
--
Ms. Amy B. Sullivan
Ms. Amy B. Sullivan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Dr. Qasim Ahmad, M.D.
Dr. Qasim Ahmad, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+70.87%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
--
Dr. Peter Hirth, Ph.D.
Dr. Peter Hirth, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Christian E. Elling, Ph.D.
Dr. Christian E. Elling, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Thu, May 14
更新時刻: Thu, May 14
株主統計
種類
株主統計
株主統計
比率
Lundbeckfond Ventures
19.39%
Kurma Partners SA
9.48%
Chernett (Jorey)
6.31%
Point72 Asset Management, L.P.
5.60%
Ikarian Capital LLC
1.93%
他の
57.29%
株主統計
株主統計
比率
Lundbeckfond Ventures
19.39%
Kurma Partners SA
9.48%
Chernett (Jorey)
6.31%
Point72 Asset Management, L.P.
5.60%
Ikarian Capital LLC
1.93%
他の
57.29%
種類
株主統計
比率
Venture Capital
28.89%
Hedge Fund
8.59%
Individual Investor
6.63%
Investment Advisor
2.83%
Investment Advisor/Hedge Fund
1.31%
Research Firm
1.29%
他の
50.46%
機関投資家保有株
更新時刻: Wed, Apr 1
更新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株式数
比率
変動額
2026Q1
56
33.96M
47.71%
-19.15M
2025Q4
52
34.65M
48.27%
-16.00M
2025Q3
49
42.06M
63.84%
-13.38M
2025Q2
52
43.99M
66.77%
-12.21M
2025Q1
56
44.00M
66.79%
+640.94K
2024Q4
57
44.61M
67.71%
+1.88M
2024Q3
50
48.46M
73.56%
+5.16M
2024Q2
48
51.73M
78.53%
+7.90M
2024Q1
53
52.99M
80.43%
+6.73M
2023Q4
55
54.27M
82.38%
+8.45M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Lundbeckfond Ventures
13.95M
19.39%
--
--
Apr 11, 2025
Kurma Partners SA
6.82M
9.48%
--
--
Apr 11, 2025
Chernett (Jorey)
4.54M
6.31%
+1.07M
+30.67%
Dec 31, 2025
Point72 Asset Management, L.P.
4.03M
5.6%
+4.03M
--
Feb 05, 2026
Ikarian Capital LLC
1.39M
1.93%
-139.33K
-9.13%
Dec 31, 2025
HBM Partners AG
3.94M
5.48%
--
--
Apr 11, 2025
BofA Global Research (US)
799.95K
1.11%
--
--
Dec 31, 2025
Morgan Stanley Smith Barney LLC
539.18K
0.75%
-129.22K
-19.33%
Dec 31, 2025
Beacon Pointe Advisors LLC
506.00K
0.7%
+506.00K
--
Dec 31, 2025
Boothbay Fund Management, LLC
451.85K
0.63%
-139.33K
-23.57%
Dec 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
